INDEPENDENT COMMUNITY PHARMACY AVERAGE Rx CHARGE ROSE 9%
Executive Summary
INDEPENDENT COMMUNITY PHARMACY AVERAGE Rx CHARGE ROSE 9% over 1985 charges, according to a preliminary Lilly Digest report previewing data that will appear in the final September publication. The report, which is based on an initial survey of 997 independent community pharmacies, found that "the average prescription charge was $14.23 during 1986, an increase of $1.19 over the 1985 figure of $13.04." Total prescriptions dispensed, which had been down 1.5% in 1985, increased 3.8% to 29,427. New prescriptions, up 4.6% at 14,730, accounted for 50.1% of total Rxs, compared to 49.7% in 1985. The average number of renewed prescriptions in 1986 rose 3.1% to 14,697. Higher Rx charges and dispensing rates together contributed to a 13.3% rise in Rx sales. Average sales were $418,601 in 1986 and $369,595 in 1985. Rx revenues accounted for 63.3% of total pharmacy sales in 1986 and 62.2% in 1985. The 13% growth in Rx sales "significantly outpaced the 8% increase in other sales," and contributed to an 11% gain in overall sales to $661,610, the preview noted. Prescription inventory was up 11.5% at $43,415, and represented 10.4% of sales, down slightly from 10.5% in 1985. Net profit rose 9.9% to $18,209, but remained stable as a percentage of sales at 2.8%.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth